Menu

Top Stories

Published on Thursday, May 28, 2015

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

The Alpha-1 Foundation on Thursday congratulated the investigators and sponsor of the RAPID Trial, demonstrating the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency, on the publication of the trial in The Lancet, one of the world’s oldest and most prestigious medical journals.

The Lancet article was posted online this week.

When the results were first announced at the international conference of the American Thoracic Society (ATS) in 2013, lead author Kenneth Chapman, MD, director of the Asthma and Airway Centre of the University Health Network in Toronto, Canada, called the trial “the most rigorous evidence to date that augmentation therapy slows the progression of emphysema in patients with Alpha-1 Antitrypsin Deficiency. The effect of A1-PI seen in this trial was both clinically and statistically significant, finally confirming its benefit in preventing the loss of lung tissue in patients with this potentially debilitating disease.”

The Alpha-1 Foundation hailed the trial results and The Lancet publication. "We congratulate CSL on this landmark clinical trial, which provides the strongest evidence yet that augmentation therapy preserves the lung tissue of individuals with Alpha-1-related lung disease," said John Walsh, Foundation president and CEO. "We hope these results will support Alpha-1 communities around the world in their efforts to win access to therapy.”

Walsh said, “The Foundation has communicated its support for acceptance of the RAPID data as proof of efficacy of augmentation therapy to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (the European equivalent of the FDA), and has continued a dialogue with both agencies to urge acceptance of these findings.”

CSL Behring sponsored the trial, which randomly assigned 180 Alpha-1 patients to receive either the augmentation product Zemaira or a placebo for a two-year period, followed by a two year of open-label extension study in which all subjects were offered augmentation therapy. “We applaud CSL for its commitment of time and effort to conduct this multinational, multi-year study, and we’re delighted that The Lancet has published the RAPID Trial results,” said Walsh. 

The Lancet article says that an interim analysis of data from the two-year extension trial suggest that early treatment with augmentation therapy shows persistent efficacy in patients with Alpha-1 and emphysema. In addition, when patients who had been receiving a placebo in the original two-year trial switched to treatment with augmentation therapy, their lung density decline (which was more rapid than the treated group in the main study) slowed to the same rate as the treatment group. “These findings should encourage early introduction of augmentation therapy [in patients with emphysema due to Alpha-1] and should stimulate further research into optimum dosing,” says the Lancet article.

Robert Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet, was a co-author of the Lancet article.

The RAPID Trial is the first well-powered randomized, placebo-controlled trial to use CT scan lung density as the primary outcome measure. CT scans are currently considered the most sensitive measure of emphysema detection. The trial was conducted at 28 sites in the United States, Europe, Canada, Australia and Russia.

The multi-center, multi-national trial randomized patients with homozygous Alpha-1 (ZZ) to receive either alpha-1 antitrypsin augmentation therapy intravenously at 60 mg/kg weekly or a placebo over two years. CT scan lung density was measured at baseline, three months, one and two years. Secondary endpoints included spirometry, changes in exercise capacity and the rate of pulmonary exacerbations over two years.

The annual rate of lung density loss was significantly less in augmentation-treated patients (-1.45 +/- 0.24 units vs. -2.19 +/-0.25 units; p = 0.017, one-sided). Secondary outcome variables and adverse events were not significantly different between groups, according to the article. There was one death in the augmentation therapy group and three in the placebo group.

Attached is the full article published in The Lancet, with an accompanying editorial by Ronald Crystal, MD, Department of Genetic Medicine, Weill Cornell Medical College.

Photo at top: Ken Chapman, MD. Below: John Walsh, left, and Robert Sandhaus, MD.


Print

Medicare Part D: Smoothing the out-of-pocket cap

Thursday, October 10, 2019
The Medicare Prescription drug benefit, or Part D, is an optional program from the Federal Government that helps older adults pay for their prescription drugs. Under Part D, the government and the individual share the cost of drugs up to a certain...
Divider

Escape to the Cape 2019: Team Alpha-1 at its best

Sunday, October 6, 2019
Even though the bike trek started with heavy hearts due to the very recent passing of two amazing Alpha volunteers, Susan Binnall and Alyce Yout, Team Alpha-1 pushed through and dedicated the ride to them: “Alyce & Sue This Rides for...
Divider

Open for comments: FDA proposes new required health warnings for cigarette packages

Tuesday, September 24, 2019
The U.S. Food and Drug Administration (FDA) issued a proposed rule to require new health warnings on cigarette packages and advertisements to promote greater public understanding of the negative health consequences of smoking. The agency...
Divider

FDA/NIH public workshop: Developing Alpha-1 Antitrypsin Therapeutics

Tuesday, September 17, 2019
The Alpha-1 Foundation is proud and grateful for the opportunity to collaborate with the FDA, Center for Biologics Evaluation and Research (CBER), and the National Institutes of Health (NIH) in organizing the public workshop entitled...
Divider

White House prepares to ban flavored e-cigs

Tuesday, September 17, 2019
The Trump administration said it is planning to ban all e-cigarette flavors following a recent nationwide outbreak of severe lung illnesses linked to vaping and five reported deaths, according to pool reports. President Donald Trump told...
Divider

Breaking a 10-year streak, the number of uninsured Americans rises

Friday, September 13, 2019
For the first time in a decade, the number of Americans without health insurance has risen — by about 2 million people in 2018 — according to the annual U.S. Census Bureau report. The Census found that 8.5% of the U.S. population...
Divider

House Speaker Nancy Pelosi to release drug pricing plan after Congress returns

Thursday, September 12, 2019
As published on the National Health Council Insider and other news outlets, House Speaker Nancy Pelosi will release a drug-pricing plan shortly after Congress returns to work after its August recess, a House Democratic aide confirmed. Democrats...
Divider

Study analyzes the degree of concordance among international guidelines regarding Alpha-1 Antitrypsin Deficiency

Thursday, September 12, 2019
The International Journal of Chronic Obstructive Pulmonary Disease recently published the outcomes of a study entitled “An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency,”...
Divider

The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: A pilot clinical trial

Thursday, September 12, 2019
The American Journal of Respiratory and Critical Care Medicine, of the American Thoracic Society (ATS), recently published an article about the outcomes of a clinical trial entitled: “Effect of Double Dose of Alpha 1-antitrypsin Augmentation...
Divider

News and updates from the U.S. COPD Coalition

Wednesday, September 11, 2019
The U.S. COPD Coalition (USCC), which the Alpha-1 Foundation is a member of, has remained engaged in issues confronting our communities and continued its collaboration with other groups to positively impact access to diagnosis, treatment, and...
Divider

FDA and NIH public workshop: Agenda now available

Wednesday, September 4, 2019
The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are sponsoring the workshop entitled “Developing Therapeutics for Alpha-1 Antitrypsin Deficiency,” at the Natcher Conference Center, Building 45...
Divider

Update: CSL Behring announcement on their product Zemaira

Monday, August 19, 2019
The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1): "CSL Behring is...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive